Vanguard VHT vs iShares IBB ETFs healthcare investing strategies compared

The Vanguard Health Care ETF (VHT) and the iShares Biotechnology ETF (IBB) offer distinct approaches to investing in the healthcare sector. VHT provides broad exposure across the industry, including pharmaceuticals, medical devices, and services, with 411 holdings. Its top positions include Eli Lilly & Co, Johnson & Johnson, and AbbVie Inc. In contrast, IBB focuses solely on biotechnology, with 243 holdings in companies like Gilead Sciences, Vertex Pharmaceuticals, and Amgen Inc.

Cost and performance differ significantly between the two funds. VHT has a lower expense ratio of 0.09% compared to IBB's 0.44%. Over the past year, IBB delivered a 49.8% return, while VHT achieved 22.5%. However, VHT offers a higher dividend yield of 1.4%, compared to IBB's 0.2%. The funds also vary in risk, with IBB showing a maximum drawdown of 39.8% over five years, versus VHT's 17.7%.

Investors with a higher risk tolerance seeking growth may prefer IBB, which offers greater exposure to biotech innovation. However, this comes with increased volatility due to regulatory and clinical risks. For those prioritizing stability and long-term holding, VHT's diversification and lower fees make it a more attractive option.

The choice between VHT and IBB ultimately depends on an investor's risk tolerance and investment goals. Both funds provide valuable exposure to the healthcare sector, but cater to different strategies and preferences.